ArticleMolecular psychiatry2026
Global burden of diseases attributed to mental and substance use disorders in reproductive-age women: an ecological analysis for the Global Burden of Disease Study 2021.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting Neuroinflammation in Depression: The Integrative Role of Sigma-1 Receptor Modulation.Journal of neurochemistry · 2026Review
- Context-dependent asymmetries in intertemporal decision-making: a comparative study of substance use disorder and control groups.Substance abuse treatment, prevention, and policy · 2026Article
- Role of Depressive Symptoms in the Expression of Self-silencing and Anger in Women.Annals of neurosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A comprehensive analysis of the global burden and trends of mental disorders (MDs) and substance use disorders (SUDs) among reproductive-age women is lacking. This study estimated the burden of disease attributable to MDs and SUDs in reproductive-age women from 1990 to 2021. Using data from the Global Burden of Disease Study 2021, we assessed the prevalence, incidence, and years lived with disability (YLDs) of 12 types of MDs and SUDs among reproductive-age women between 1990 and 2021. Estimates were stratified by age and sex at global, regional, and national levels. Trends were evaluated using the average annual percentage change (AAPC) and total percentage change. In 2021, the global age-standardized prevalence rates per 100,000 population among reproductive-age women were 17,573 (95% uncertainty interval 15,443-19,954) for MDs and 1806 (95% uncertainty interval 484-2191) for SUDs. Among MDs, depressive and anxiety disorders were the leading contributors to YLDs, with age-standardized YLD rates of 1,073.5 (686.73-1,562.48) and 844.05 (532.79-1,232.57) per 100,000 population, respectively. From 1990 to 2021, age-standardized rates of the prevalence, incidence, and YLDs of MDs increased (AAPC: 35%, 55%, and 38%, respectively), while those of SUDs decreased (AAPC: -55%, -62%, and -19%, respectively). The burden of both MDs and SUDs was highest in regions with higher sociodemographic indices. The greatest increases in burden were observed among younger women aged 15-24 years with MDs and 15-34 years with SUDs. MDs and SUDs are substantial contributors to the global disease burden in reproductive-age women. The magnitude and distribution of this burden vary by disorder type, country, age group, and sociodemographic development.
Indexed as
Identifiers
40921795What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.